RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR

Small cell lung cancer (SCLC) is an aggressive cancer that represents ~15% of all lung cancers. Currently there are no targeted therapies to treat SCLC. Our genomic analysis of a metastatic SCLC cohort identified recurrent RICTOR amplification. Here, we examine the translational potential of this ob...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Sakre, Nneha, Wildey, Gary, Behtaj, Mohadese, Kresak, Adam, Yang, Michael, Fu, Pingfu, Dowlati, Afshin
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2016
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5351607/
https://ncbi.nlm.nih.gov/pubmed/27863413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13362
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы